Endocrine Abstracts

Objective: To evaluate the alterations of fibrosis biomarkers during empagliflozin treatment in patients with type 2 diabetes mellitus (T2DM) and a very high risk of cardiovascular events.Materials and methods: Twenty-six patients with type 2 diabetes mellitus received 10 mg of empagliflozin within 24 weeks. Inclusion criteria: women and men aged 18 to 70 years with T2DM, glycated hemoglobin (HbA1c) 7.0–11.0%, stable hypoglycemic therapy at least 1...

Recently, sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardioprotective effects. However, findings for major adverse CV events (MACE) outcomes with dapagliflozin are not concordant with the empagliflozin studies and the possible mechanisms of cardioprotective effects are not fully understood. The aim of the study was to compare the two distinct SGLT2i, empagliflozin and dapagliflozin, in their influence on the biomarkers of fibrosis and inflammation.</p...